Abstract:Protein kinases play pivotal roles in various biological functions, influencing cell differentiation, promoting survival, and regulating the cell cycle. The disruption of protein kinase activity is intricately linked to pathways in tumor development. This manuscript explores the transformative impact of protein kinase inhibitors on cancer therapy, particularly their efficacy in cases driven by targeted mutations. Focusing on key tyrosine kinase inhibitors (TKIs) like Bcr-Abl, Epidermal Growth Factor Receptor (EGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR), it targets critical kinase families in cancer progression. Clinical trial details of these TKIs offer insights into their therapeutic potentials. Learning from FDA-approved kinase inhibitors, the review dissects trends in kinase drug development since imatinib's paradigm-shifting approval in 2001. TKIs have evolved into pivotal drugs, extending beyond oncology. Ongoing clinical trials explore novel kinase targets, revealing the vast potential within the human kinome. The manuscript provides a detailed analysis of advancements until 2022, discussing the roles of specific oncogenic protein kinases in cancer development and carcinogenesis. Our exploration on PubMed for relevant and significant TKIs undergoing pre-FDA approval phase III clinical trials enriches the discussion with valuable findings. While kinase inhibitors exhibit lower toxicity than traditional chemotherapy in cancer treatment, challenges like resistance and side effects emphasize the necessity of understanding resistance mechanisms, prompting the development of novel inhibitors like osimertinib targeting specific mutant proteins. The review advocates thorough research on effective combination therapies, highlighting the future development of more selective RTKIs to optimize patient-specific cancer treatment and reduce adverse events.

The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020

An update of new small-molecule anticancer drugs approved from 2015 to 2020

Dynamic adaptation of the blind pointing characteristic to stepwise lateral tilts of body, head, and trunk

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Research Progress in Quinazoline Derivatives As Multi-Target Tyrosine Kinase Inhibitors

Urethral obstruction in cats: Predisposing factors, clinical, clinicopathological characteristics and prognosis

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

CADD Methods for Developing Novel Compounds Synthesized to Inhibit Tyrosine Kinase Receptors

Tyrosine kinase inhibitors in cancer treatment (Part II)

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I

Current Status of Research and Development of New Tyrosine Kinase Inhibitors

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Advances in the Research of Small Molecule Tyrosine Kinase Inhibitors

Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice

Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

Letter: Selection of medical students by lottery.

Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy